Tagged with USA,

USA The US drug-price watchdog, The Institute for Clinical & Economic Review (ICER) recently issued a “Report on Unsupported Price Increases,” picking a number of innovative medicines that it says have seen price hikes without sufficient substantiation. While the study made the headlines, Certara’s Ulrich Neumann calls for some scepticism and…

UAE The UAE is putting a greater emphasis on healthcare than ever before as part of its ‘Vision 2021’ model. With the aim of being “flexible in adopting new economic models and capitalizing on global economic partnerships,” the Emirates are seeing greater numbers of investments and partnerships in healthcare, many of…

Opinion Sophia Ononye outlines the history of cannabis as a medicine in the US and, following the first FDA approval of a cannabis-derived drug product in 2018, the highly promising landscape for further approvals.   The landscape for approved CBD products is highly promising and will undoubtedly lead to additional FDA…

USA Although Boston and California may be more internationally renowned as biotech hubs, New York is fast catching up. Thanks in large part to its strong scientific and business infrastructure and easy access to capital, growing numbers of early-stage biotechs are choosing to base their operations in New York and list…

USA Jennifer Hawks Bland of NewYorkBIO, the premier trade association for the life sciences in New York State, discusses the association’s diverse list of members, the services it provides them, and how New York is building a bio-ecosystem to rival those of Boston and California.   We have the unique ability…

Opinion Krishna Cheriath, chief data officer at BMS, outlines the ways in which AI is already transforming the delivery of healthcare, what modern biopharma companies’ AI innovation agendas should include, and why behavioural change is a key tenet in securing meaningful health outcomes with AI.   As Biopharma increases AI investments,…

USA In the face of rising costs in American healthcare, Carla Smith outlines five ways in which the US can improve the financial sustainability of its healthcare system.   Let’s take advantage of systems-level expertise and change our reality for the better In the United States, 18 percent of the gross…

USA PhRMA’s Anne McDonald Pritchett PhD highlights the remarkable development of cell and gene therapies in recent years and the three ways in which the US healthcare system can better accommodate them: creating manufacturing systems that take treatment timelines into account, a health system that values treatments based on patient outcomes,…

USA In a bid to make tangible progress on the issue of lowering prescription drug pricing before the 2020 presidential election, the Trump administration is planning to import cheaper medicines from Canada and elsewhere. However, as the Eurasia Group’s Aditya Bhattacharji and Sandra Yamin Namoos outline, the proposed plan’s impact on…

USA PwC’s Kelly Barnes examines how the US pharmaceutical sector is having to rethink its relationship with consumers, experimenting with new and innovative pricing models, and adopting a more holistic view of the patients using their medicines.   American consumers want more than just lower prices from pharmaceutical companies US Consumers…

USA Eurasia Group’s Aditya Bhattacharji looks at the potentially damaging fallout of the ongoing US-China trade war on the life sciences industry.   Biotech [is the] new frontier for US-China tensions The G20 gathering in Osaka at the end of June was, overall, less tense than other multilateral fora over the…

USA The bestselling drugs of 2018 in the USD 485 billion US pharma market. The list features several major blockbusters benefiting from the delays in biosimilar approval in the US, as well as several small-molecule medications that stand to lose out to generic competition in the coming years. AbbVie’s Humira is…